Patents by Inventor Andrew J. Thorpe

Andrew J. Thorpe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prodrugs of amino acids with affinity for the ?2?-protein
    Patent number: 7491835
    Abstract: This invention relates to prodrugs of certain amino acids that bind to the alpha-2-delta (?2?) subunit of a calcium channel. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders.
    Type: Grant
    Filed: September 21, 2004
    Date of Patent: February 17, 2009
    Assignee: Pfizer Inc
    Inventors: Sean D. Donevan, Augustine Tobi Osuma, Andrew J. Thorpe, David Juergen Wustrow
  • Selective &bgr;3 adrenergic agonists
    Patent number: 6686372
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr;3 receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: April 10, 2002
    Date of Patent: February 3, 2004
    Assignee: Eli Lilly and Company
    Inventors: Thomas A. Crowell, Deborah A. Evrard, Charles D. Jones, Brian S. Muehl, Christopher J. Rito, Anthony J. Shuker, Andrew J. Thorpe, Kenneth J. Thrasher
  • Selective B3 adrenergic agonists
    Publication number: 20020165234
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr;3 receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Application
    Filed: April 10, 2002
    Publication date: November 7, 2002
    Inventors: Thomas A. Crowell, Deborah A. Evrard, Charles D. Jones, Brian S. Muehl, Christopher J. Rito, Anthony J. Shuker, Andrew J. Thorpe, Kenneth J. Thrasher
  • Selective &bgr;3 adrenergic agonists
    Patent number: 6413991
    Abstract: Disclosed herein are selective beta 3 adrenergic agonists represented by the following structural formula: The variables in the structural formula shown above are defined in the specification. Also disclosed are methods of using these compounds for agonizing the beta 3 adrenergic receptor in patients in need of such treatment, for example, patients in need of treatment for obesity or Type II diabetes.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: July 2, 2002
    Assignee: Eli Lilly and Company
    Inventors: Thomas A. Crowell, Deborah A. Evrard, Charles D. Jones, Brian S. Muehl, Christopher J. Rito, Anthony J. Shuker, Andrew J. Thorpe, Kenneth J. Thrasher
  • Carbazolyl-substituted ethanolamines as selective .beta.-.sub.3 agonists
    Patent number: 6140352
    Abstract: Disclosed herein are selective beta 3 adrenergic agonists represented by the following structural formula: ##STR1## The variables in the structural formula shown above are defined in the specification. Also disclosed are methods of using these compounds for agonizing the beta 3 adrenergic receptor in patients in need of such treatment, for example, patients in need of treatment for obesity or Type II diabetes.
    Type: Grant
    Filed: May 4, 1998
    Date of Patent: October 31, 2000
    Assignee: Eli Lilly and Company
    Inventors: Thomas A. Crowell, Deborah A. Evrard, Charles D. Jones, Brian S. Muehl, Christopher J. Rito, Anthony J. Shuker, Andrew J. Thorpe, Kenneth J. Thrasher